ArticleBritish journal of haematology2025
Empirical and projected economic burden of chronic myeloid leukaemia in Sweden from 2015 to 2030: A population-based study.
Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Empirical and projected economic burden of chronic myeloid leukaemia in Sweden from 2015 to 2030: A population-based study.British journal of haematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Despite therapeutic advances and improved survival, the long-term economic burden of chronic myeloid leukaemia (CML) remains under-recognised given evolving treatment practices and fluctuating drug costs. We aimed to estimate and project total prevalence costs for CML in Sweden from a healthcare sector perspective, representing the direct healthcare expenditures for all patients living with CML, based on real-world drug and procedure prices. We used data from the Swedish Cancer Register and the Swedish CML register to estimate and project prevalence and costs. The estimated numbers of prevalent cases were 1808 (95% confidence interval [CI], 1604-2011) in 2025 and 2120 (95% CI, 1916-2325) in 2030, driven by stable incidence and improved survival. Despite increasing prevalence, the annual total direct healthcare costs for all prevalent CML patients in Sweden decreased from USD 40.04 million (95% CI, 33.70-46.40) in 2015 to USD 26.04 million (95% CI, 23.13-28.97) in 2025, then projected to slightly increase to USD 30.67 million (95% CI, 27.70-33.64) in 2030. While CML prevalence proportions are expected to increase, declining treatment costs may mitigate the burden on the Swedish healthcare system. These population-based projections can inform long-term planning and pricing strategies for CML care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.